Advertisement
Canada markets open in 4 hours 57 minutes
  • S&P/TSX

    21,947.41
    +124.21 (+0.57%)
     
  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     
  • DOW

    38,675.68
    +449.98 (+1.18%)
     
  • CAD/USD

    0.7312
    +0.0003 (+0.04%)
     
  • CRUDE OIL

    78.86
    +0.75 (+0.96%)
     
  • Bitcoin CAD

    89,421.96
    +2,111.17 (+2.42%)
     
  • CMC Crypto 200

    1,392.58
    +79.96 (+6.09%)
     
  • GOLD FUTURES

    2,329.50
    +20.90 (+0.91%)
     
  • RUSSELL 2000

    2,035.72
    +19.61 (+0.97%)
     
  • 10-Yr Bond

    4.5000
    -0.0710 (-1.55%)
     
  • NASDAQ futures

    18,022.75
    +22.00 (+0.12%)
     
  • VOLATILITY

    13.99
    +0.50 (+3.71%)
     
  • FTSE

    8,213.49
    +41.34 (+0.51%)
     
  • NIKKEI 225

    38,236.07
    -38.03 (-0.10%)
     
  • CAD/EUR

    0.6783
    -0.0004 (-0.06%)
     

Relay Therapeutics to Participate in Upcoming Investor Conferences

Relay Therapeutics, Inc.
Relay Therapeutics, Inc.

CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in three upcoming fireside chats:

  • Stifel 2024 Virtual Targeted Oncology Forum on Wednesday, April 17, 2024 at 1:00 p.m. ET

  • The Citizens JMP Life Sciences Conference on Tuesday, May 14, 2024 at 11:30 a.m. ET

  • BofA Securities Health Care Conference 2024 on Tuesday, May 14, 2024 at 1:40 p.m. PT

The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available for up to 30 days following the event.

ADVERTISEMENT

About Relay Therapeutics

Relay Therapeutics is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo™ platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.

Contact:
Megan Goulart
617-545-5526
mgoulart@relaytx.com

Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com